These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31515669)

  • 21. Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
    Zhang Y; Liu J; Raj-Kumar PK; Sturtz LA; Praveen-Kumar A; Yang HH; Lee MP; Fantacone-Campbell JL; Hooke JA; Kovatich AJ; Shriver CD; Hu H
    Breast Cancer Res Treat; 2020 Dec; 184(3):689-698. PubMed ID: 32880016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. G Protein-Coupled Estrogen Receptor Correlates With Dkk2 Expression and Has Prognostic Impact in Ovarian Cancer Patients.
    Fraungruber P; Kaltofen T; Heublein S; Kuhn C; Mayr D; Burges A; Mahner S; Rathert P; Jeschke U; Trillsch F
    Front Endocrinol (Lausanne); 2021; 12():564002. PubMed ID: 33679613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The molecular prognostic score, a classifier for risk stratification of high-grade serous ovarian cancer.
    Sarkar S; Saha SA; Swarnakar A; Chakrabarty A; Dey A; Sarkar P; Banerjee S; Mitra P
    J Ovarian Res; 2024 Aug; 17(1):159. PubMed ID: 39095849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
    Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
    BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer.
    Wang B; Chao S; Guo B
    J Clin Lab Anal; 2022 Feb; 36(2):e24165. PubMed ID: 34997982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune cell landscapes are associated with high-grade serous ovarian cancer survival.
    Zhang G; Zhang Y; Zhang J; Yang X; Sun W; Liu Y; Liu Y
    Sci Rep; 2024 Jul; 14(1):16140. PubMed ID: 38997411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment.
    Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q
    Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.
    Rody A; Holtrich U; Pusztai L; Liedtke C; Gaetje R; Ruckhaeberle E; Solbach C; Hanker L; Ahr A; Metzler D; Engels K; Karn T; Kaufmann M
    Breast Cancer Res; 2009; 11(2):R15. PubMed ID: 19272155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
    Murakami R; Matsumura N; Mandai M; Yoshihara K; Tanabe H; Nakai H; Yamanoi K; Abiko K; Yoshioka Y; Hamanishi J; Yamaguchi K; Baba T; Koshiyama M; Enomoto T; Okamoto A; Murphy SK; Mori S; Mikami Y; Minamiguchi S; Konishi I
    Am J Pathol; 2016 May; 186(5):1103-13. PubMed ID: 26993207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.
    Lee M; Nam EJ; Kim SW; Kim S; Kim JH; Kim YT
    Int J Gynecol Cancer; 2012 Nov; 22(9):1489-96. PubMed ID: 23095773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer.
    De Donato M; Babini G; Mozzetti S; Buttarelli M; Ciucci A; Arduini G; De Rosa MC; Scambia G; Gallo D
    J Exp Clin Cancer Res; 2020 Nov; 39(1):265. PubMed ID: 33250051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of intra-tumoral budding in high-grade serous ovarian carcinomas.
    Hachisuga T; Murakami M; Harada H; Ueda T; Kurita T; Kagami S; Yoshino K; Tajiri R; Hisaoka M
    Sci Rep; 2022 Feb; 12(1):3153. PubMed ID: 35210538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrative and Comprehensive Pan-Cancer Analysis of Lymphocyte-Specific Protein Tyrosine Kinase in Human Tumors.
    Han M; Li Y; Guo Y; Zhu W; Jiang J
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A centrosome clustering protein, KIFC1, predicts aggressive disease course in serous ovarian adenocarcinomas.
    Mittal K; Choi DH; Klimov S; Pawar S; Kaur R; Mitra AK; Gupta MV; Sams R; Cantuaria G; Rida PCG; Aneja R
    J Ovarian Res; 2016 Mar; 9():17. PubMed ID: 26992853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites.
    Feigenberg T; Clarke B; Virtanen C; Plotkin A; Letarte M; Rosen B; Bernardini MQ; Kollara A; Brown TJ; Murphy KJ
    Biomed Res Int; 2014; 2014():367103. PubMed ID: 24982872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer.
    Gong W; Liu Y; Diamandis EP; Kiechle M; Bronger H; Dorn J; Dreyer T; Magdolen V
    J Ovarian Res; 2020 Oct; 13(1):125. PubMed ID: 33087135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma.
    Yuan D; Zhu H; Wang T; Zhang Y; Zheng X; Qu Y
    Eur J Med Res; 2023 Oct; 28(1):465. PubMed ID: 37884970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
    Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
    Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Th2 cells infiltrating high-grade serous ovarian cancer: a feature that may account for the poor prognosis.
    Su H; Jin Y; Tao C; Yang H; Yang E; Zhang WG; Feng F
    J Gynecol Oncol; 2023 Jul; 34(4):e48. PubMed ID: 36998223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.
    Callahan MJ; Nagymanyoki Z; Bonome T; Johnson ME; Litkouhi B; Sullivan EH; Hirsch MS; Matulonis UA; Liu J; Birrer MJ; Berkowitz RS; Mok SC
    Clin Cancer Res; 2008 Dec; 14(23):7667-73. PubMed ID: 19047092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.